Targeted therapy for patients with activating BRAF mutations has demonstrated the potential for personalized medicine in patients with metastatic melanoma. Initial study results were promising and dramatic.
David Howard
Articles by David Howard
Latest Updated Articles
What’s Next With Next-Generation BRAF Inhibitors?Published: April 15th 2014 | Updated: April 18th 2020